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Abstract 
 
Aim: Four non-vitamin K oral anticoagulants (NOACs) have been evaluated in clinical trials 
for the prevention of stroke in patients with atrial fibrillation (AF). Although each of the 
NOACs have been shown to be at least non-inferior to warfarin for efficacy and safety 
outcomes, controversy remains over the relative safety of each NOAC in patient subgroups. 
This narrative review provides an overview of phase III data on NOAC trials for the 
prevention of stroke in AF, with a focus on reporting the safety of each agent in key patient 
subgroups based on age, gender, accumulated risk factors, and primary or secondary 
prevention of stroke.  
Methods: A comprehensive literature search was completed and, where data permit, 
analyses of phase III trials of the NOACs are presented for each patient subgroup. 
Results: Analyses of key safety outcomes from NOAC trials were completed using primary 
trial data, including major bleeding and all-cause mortality. The safety of NOACs was 
generally consistent and favourable compared to warfarin according to patient age, gender, 
previous history of stroke, and the presence of risk factors for stroke.   
Conclusions: The safety of the NOACs compared to warfarin was generally favourable 
across different patient subgroups, including those perceived to be at ‘high risk’ for adverse 
outcomes. However, certain NOACs may be preferable to warfarin in some subgroups, 
based on indirect analyses.  
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Review criteria: 
 
 A comprehensive literature search was completed using online databases. 
 Primary study data were extracted and analysed.  
 
Take home message: 
 NOACs generally have a favourable safety profile to warfarin in all patient subgroups. 
 Some NOACs may have better safety profiles than others based on indirect 
analyses. 
 
Introduction 
 
Atrial fibrillation (AF) is associated with an increased risk of morbidity and mortality, in part 
due to an increased risk of stroke in this population (1,2). AF increases the risk of stroke 
five-fold compared to the general population (1). Accordingly, lifelong anticoagulation 
therapy is recommended for patients with AF (3).Typically, this has involved the use of 
vitamin K antagonists, primarily warfarin (4). Well-controlled warfarin therapy has been 
shown to be highly effective in the prevention of stroke in patients with AF and is associated 
with a relative risk reduction of 64% compared with control/placebo, as well as a 26% 
reduction in all cause mortality (5). 
 
However, achieving well-controlled warfarin therapy in practice is a demanding process 
(6,7). Warfarin has a narrow therapeutic range, defined as an international normalised ratio 
(INR) of 2.0–3.0 and this time in therapeutic range (TTR) should be achieved for >70% of 
the treatment period to ensure optimal outcomes (7). When the INR is too low, the risk of 
stroke increases, while an elevated INR increases the risk of bleeding (8,9). Maintaining the 
INR within this range is complicated by the multiple drug and food interactions observed with 
warfarin therapy, as well as significant intra- and inter-individual variability in the 
pharmacological profile of the drug and the healthcare system in which a service operates 
(6,7). Multiple commonly occurring risk factors have been defined and prospectively 
validated, predicting a failure to achieve TTR (10). The risk of bleeding on warfarin therapy is 
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one of the most significant concerns of patients and physicians, due to the morbidity and 
mortality associated with major bleeding events (7,11). Therefore, anticoagulation therapy 
with the non-vitamin K oral anticoagulants (NOACs), which do not require routine 
anticoagulant monitoring and have a more predictable pharmacological profile, may be 
practically advantageous and more acceptable to patients compared to warfarin therapy. 
 
Four NOACs are licenced for use in patients with non-valvular AF in the United States and 
Europe: apixaban, dabigatran, edoxaban, and rivaroxaban. Evidence from phase III trials 
suggests that the NOACs have a favourable efficacy and safety profile compared with 
warfarin (12).  Whilst there have not be direct comparisons with antiplatelet drugs or placebo 
(apart from apixaban (13)), indirect comparisons clearly show superior efficacy and the 
safety of NOACs versus antiplatelet drugs or placebo (14). 
 
However, it is recognised that the efficacy and safety profiles of anticoagulant therapy are 
not homogeneous in the AF population. Different patient risk factors may contribute towards 
an increased risk of stroke or bleeding (15). It is important that these risk factors are 
identified and factored into clinical decision-making, as the risk of bleeding complications 
remains a significant reason for avoiding anticoagulation therapy in eligible patients (16,17).  
 
Bleeding risk factors have been identified by multiple bleeding risk scoring schemes, 
including the HAS-BLED score (18) which allows for identification of modifiable risk factors 
prior to initiation of anticoagulation therapy and to ‘flag up’ those at high bleeding risk for 
early review and follow up (eg. 4 weeks rather than 4-6 months) (19). Clarifying the relative 
safety profiles of the NOACs compared with warfarin and other the other agents from the 
NOAC class in individual patient populations will be vital in promoting the appropriate use of 
anticoagulant therapy in the future.  
 
Despite the available data supporting the use of NOACs as an alternative to warfarin in 
patients with AF, there are significant gaps in the knowledge base. Of particular concern, is 
the lack of data that allow physicians to differentiate between specific NOACs based on 
individual patient characteristics (20). Certain patient subgroups may be associated with 
different relative risks of stroke and/or bleeding with anticoagulation (21). Both the American 
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College of Chest Physicians (ACCP) (22) and the National Institute for Health and Care 
Excellence (NICE) (23) in the UK suggest the need for tailored NOAC recommendations to 
reflect the differences of efficacy and safety of each NOAC in different patient risk profiles, 
and consideration of patient choice.  
 
Determining the most appropriate NOAC for these subgroups requires a careful assessment 
of the net clinical benefit of each agent in the context of patient-specific factors (24). 
However, head-to-head trials of the NOACs are non-existent, disempowering physicians 
aiming to tailor therapy to the needs of the patient. The recent 2018 ACCP guidelines also 
makes suggestions for particular OAC drugs to fit the patient clinical profile, based on 
subgroup data from trials and real world postmarketing observational evidence (25) 
 
The use of NOACs in the management of valvular AF is controversial, and warfarin use 
persists in this diverse population. However, evaluation of clinical trial data (26) suggests 
that NOACs may be an alternative to warfarin in patients with AF and native aortic valve 
disease, tricuspid valve disease, or mitral regurgitation, and a CHA2DS2-VASc score of 2 or 
greater, leading to incorporation of these indications in recent guidelines for valvular heart 
disease (27).  A recent consensus guideline notes that the term ‘valvular AF’ is obsolete, 
and should be replaced by the term ‘AF with valvular heart disease’, further categorised into 
Evaluated Heartvalves, Rheumatic or Artificial (EHRA) Type I and Type II, depending on the 
possible use (or not) of NOACs (28). EHRA Type I refers to patients with valvular heart 
disease needing VKA therapy (mitral stenosis and mechanical prostheses), while EHRA 
Type II refers to patients with valvular heart disease needing therapy with VKA or NOAC, 
taking into consideration CHA2DS2VASc score risk factor components. 
 
Thus, there may be an emerging role for NOACs in this patient group, consistent with the 
general principle of minimising the elevated bleeding risk seen with the use of any 
anticoagulant in these patients.   
 
The aim of this narrative review is to provide an overview of existing clinical trial data on 
NOACs for patients with AF, focusing on the safety of NOACs in specific patient subgroups. 
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Analyses of available data are presented to provide objective, indirect comparisons between 
NOACs, thereby highlighting the roles of each NOAC in specific patient subgroups.  
  
Methodology 
This review examined data pertaining to four NOACs (apixaban, dabigatran, edoxaban and 
rivaroxaban) evaluated in phase III trials, assessing the favourability of agents in specific 
patient subgroups for the treatment of AF, using pooled analyses where appropriate. Study-
specific event rates among patient subgroups were pooled using a fixed effects meta-
analysis model. Statistical heterogeneity across the trials was found to be minimal, as 
assessed using the I2 statistic. In the absence of reported effect estimates, risk ratios were 
calculated from raw data in every available trial.  
 
The phase III NOAC trials, and beyond 
 
Four main NOAC trials have been conducted in the context of the management of AF. 
Overall, the NOAC trials demonstrate that each agent is at least non-inferior to warfarin for 
the prevention of stroke/systemic embolic events (SEE) and with respect to bleeding safety 
endpoints, compared with warfarin therapy (13,29–31). Results of the NOAC trials are 
summarised in table 1. Although these trials are similar in many respects, there are 
important differences in trial design, study participants and outcome measures that should 
be considered, and have been the subject of numerous reviews (32–34).  
 
There have not been any head-to-head clinical trials of the NOACs, and apart from the 
AVERROES trial comparing apixaban to aspirin in patients ineligible for (or refusing) VKA 
(13) there have been no direct comparisons of dabigatran, rivaroxaban or edoxaban against 
aspirin or placebo. The AVERROES trial was stopped early due to a clear superiority of 
apixaban over aspirin for reducing stroke/SEE, with no significant difference in major 
bleeding or ICH (13).   
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Indirect comparisons of the NOACs have shown that the efficacy of apixaban, dabigatran 
(both doses) and rivaroxaban is comparable, but dabigatran 150 mg BID was superior to 
rivaroxaban for some efficacy endpoints, while major bleeding was lower with dabigatran 
110 mg BID or apixaban (35). Rasmussen and colleagues (36) found that apixaban, 
dabigatran and rivaroxaban had similar efficacy for the main endpoints when used for 
secondary stroke prevention. However, haemorrhagic stroke, vascular death, major bleeding 
and intracranial bleeding were less common with dabigatran 110 mg BID than with 
rivaroxaban. For primary prevention of stroke, apixaban was associated with less major 
bleeding than dabigatran 150 mg BID and rivaroxaban less and gastrointestinal bleeding 
than dabigatran 150 mg BID (36). 
 
An indirect analysis (37) including edoxaban has also been published, demonstrating that 
both high- and low-dose regimens of edoxaban have comparable efficacy and safety to 
apixaban, dabigatran and rivaroxaban, although some differential effects were evident (e.g. 
lower rates of stroke/SEE but a higher rate of major bleeding with apixaban versus low dose 
regimen edoxaban). Blann et al. (38) have shown that both 30 mg and 60 mg doses of 
edoxaban have a favourable net clinical benefit (NCB) compared with no treatment, which is 
superior to the NCB of warfarin versus no treatment.  
 
With regard to indirect comparisons of NOACs against aspirin or placebo a network meta-
analysis of nine phase III trials found that primary efficacy endpoints were consistently 
inferior with aspirin compared with the NOACs (39). Similarly, a recent network meta-
analysis found that all NOACs were superior to aspirin or placebo for stroke prevention, 
while aspirin, apixaban, dabigatran 110 mg and edoxaban were associated with less major 
bleeding than warfarin (40). Dabigatran has also been shown to have benefits for the 
prevention of stroke/SEE and mortality over antiplatelets and placebo, based on indirect 
evidence, without an indication of increased risk of ICH (41). Similarly, indirect evidence 
supports the use of edoxaban over placebo, aspirin alone or aspirin plus clopidogrel based 
on a reduction in stroke/SEE and mortality, as well as a reduction in ICH compared with 
aspirin plus clopidogrel (14). 
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The randomised trials and network meta-analyses are now augmented by numerous real 
world data analyses that have examined the effectiveness and safety of NOACs compared 
to warfarin, as well as comparative effectiveness of the NOACs against each other.  The 
numbers of papers have largely reflected the sequence these drugs have been approved 
and licensed for clinical use. 
 
For the comparisons of NOACs versus warfarin, various studies have reported the 
effectiveness and safety of dabigatran compared to warfarin (42–44) that have been 
summarised in a systematic review and meta-analysis (45). The latter shows that dabigatran 
was associated with a lower risk of ischaemic stroke than VKA therapy as well as a lower 
risk of major bleeding (HR, 0.79; 95%CI, 0.69–0.89), intracranial bleeding (HR, 0.45; 95%CI, 
0.38–0.52) and mortality (HR, 0.73; 95%CI, 0.61–0.87). The risk of gastrointestinal bleeding 
was higher with dabigatran and the risk of myocardial infarction was comparable between 
groups.  
 
For rivaroxaban, real world data such as the XANTUS study (46) shows that the rates of 
stroke and major bleeding are low in patients taking rivaroxaban (0.7 and 2.1 events per 100 
patient-years, respectively). An analysis of the Dutch subset of the XANTUS registry (47) 
also shows a low major bleeding rate in patients taking rivaroxaban in routine clinical 
practice (2.4 events per 100 patient-years).  
 
For apixaban a real-world propensity-matched analysis of 76,940 patients with AF showed 
that apixaban initiators had a lower risk of stroke/SEE (HR, 0.67; 95%CI, 0.59–0.76) and 
major bleeding (HR, 0.60; 95CI, 0.54–0.65) than warfarin initiators (48). These findings were 
consistent across all analysed patient subgroups and subtypes of stroke/SEE and major 
bleeding. A recent analysis of the safety and effectiveness of apixaban versus VKA therapy 
in routine German practice evaluated the composite endpoint of ischaemic stroke, TIA, 
myocardial infarction or intracranial haemorrhage in one year after initiation of therapy (49). 
The findings suggested that apixaban and VKA therapy had a similar impact on this 
endpoint.  
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Two recent real-world evaluations of edoxaban versus warfarin therapy have been 
published, and show that edoxaban is likely to be associated with a reduced risk of 
ischaemic stroke, major haemorrhage and all-cause death compared with warfarin, even in 
high risk subgroups (50) and for both doses of edoxaban, although low-dose edoxaban 
(30/15 mg) had lower effectiveness for the prevention of stroke compared with warfarin 
where creatinine clearance was above 95 mL/min, suggesting that the higher dose regimen 
(60/30 mg) should be used in this group to maintain efficacy, while preserving safety (51).  
 
Comparative effectiveness and safety studies have been published between the NOACs and 
warfarin. The REVISIT-US study (52) evaluated real-world effectiveness and safety of 
apixaban or rivaroxaban versus warfarin and found that both drugs were associated with a 
reduction in the combined endpoint of stroke or intracranial haemorrhage compared with 
warfarin. However, ischaemic stroke was non-significantly increased with apixaban versus 
warfarin (HR, 1.13; 95% CI, 0.49–2.63), but small numbers and the short followup preclude 
over-interpretation of these data. A real-world analysis of claims databases in the United 
States found no difference in the risk of stroke/SEE between apixaban, dabigatran and 
rivaroxaban (53). Apixaban was associated with a lower risk of major bleeding than 
dabigatran or rivaroxaban, while rivaroxaban was associated with an increased risk of major 
bleeding and intracranial bleeding compared with dabigatran.  
 
Yao and colleagues (54) found that apixaban was associated with lower risks of stroke/SEE 
and major bleeding compared with warfarin, while stroke/SEE risk was similar between 
warfarin, dabigatran and rivaroxaban and major bleeding was lower with dabigatran. It has 
also been shown that among newly anticoagulated patients, apixaban and dabigatran were 
associated with a lower risk of major bleeding compared to warfarin initiation, while 
rivaroxaban was associated with a higher risk of major bleeding compared with apixaban 
(55). An analysis of 118,891 patients also found that rivaroxaban treatment was associated 
with an increased risk of intracranial haemorrhage and major extracranial bleeding, including 
major gastrointestinal bleeding, compared with dabigatran treatment (56).  
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High risk patient subgroups from the RCTs 
 
The remainder of this paper will focus on four key patient subgroups that are of particular 
importance when considering anticoagulation therapy in patients with AF. These subgroups 
are: elderly patients, female patients, patients with a high number of stroke risk factors, and 
patients with previous stroke. For each subgroup, a detailed examination of the available 
literature is provided, accompanied by a novel analysis of raw trial data, aimed at 
supplementing available knowledge on the safety of NOACs for each subgroup.  
 
Age 
Patient age is considered one of the major risk factors for stroke and bleeding in the context 
of anticoagulation therapy for AF (57).  The majority of patients with AF are aged over 60 
years, with approximately one-third ≥75 years old (58). It is estimated that at least 10% of 
patients over the age of 75 years have AF (59). The risk of major bleeding increases with 
age in patients with AF, particularly when receiving anticoagulation therapy (60,61). An 
increased risk of stroke has been related to underuse of anticoagulation in the elderly 
population, with one study demonstrating 75% of AF patients aged <75 years receiving 
anticoagulation following a stroke compared with 33% of patients aged >85 years, based on 
hospital admission records (62). Furthermore, one study has found that rates of warfarin 
prescription declined with increasing age on hospital discharge and that age was the single 
greatest reason cited for non-prescription of warfarin in the elderly (63). This is despite the 
finding that the clinical benefit of anticoagulation is greatest in the most elderly patients (> 85 
years old) (64). This is a worrying phenomenon, suggesting under-treatment of patients with 
AF, particularly as the relative benefits of anticoagulation tend to outweigh the potential 
negative effects, regardless of age (12).  
 
Analyses of phase III trials have suggested that the efficacy and safety of the NOACs remain 
favourable compared to warfarin, even in patients aged ≥75 years old (Table 2). In the 
subgroup analysis of the ROCKET-AF, efficacy and safety data for patients aged ≥75 years 
was consistent with the overall results of the study (65). A subgroup analysis of older 
patients (65-74 years and ≥75 years) in the ARISTOTLE trial found that stroke/systemic 
embolic events (SEE) and major bleeding outcomes were consistent with those seen in 
younger patients and the general study population (66). In both ROCKET-AF and 
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ARISTOTLE, doses of NOACs were not adjusted based on patient age. However, for RE-LY 
and ENGAGE AF-TIMI 48, a number of patients aged ≥75 years old underwent pre-specified 
dose reductions (150mg to 110mg for dabigatran and 60mg to 30mg for the high-dose 
edoxaban regimen). In the RE-LY subgroup analysis, both doses of dabigatran (150mg and 
110mg) were associated with a reduction in stroke/SEE comparable to warfarin therapy, 
regardless of patient age, while the risk of intracranial haemorrhage was reduced with both 
doses of dabigatran compared with warfarin therapy (110mg: 0.37% per year; 150mg: 
0.41% per year; versus 1.00% per year on warfarin therapy). However, there was an 
increased risk of extracranial bleeding with both doses of dabigatran in older patients 
compared with warfarin therapy (67). 
 
For edoxaban, the overall findings of the ENGAGE AF-TIMI 48 trial showed that edoxaban 
was non-inferior to warfarin for the prevention of stroke/SEE and was associated with a 
lower rate of major bleeding compared to warfarin, regardless of patient age (30). A more 
detailed analysis has been conducted of patients stratified according to age: <65, 65 to 74, 
and ≥75 years (68). This analysis found that, in patients aged ≥75 years, edoxaban and 
warfarin therapy were associated with similar rates of stroke/SEE (Hazard ratio [HR], 0.83; 
95% CI 0.66–1.04) but the risk of major bleeding was significantly lower with edoxaban (HR, 
0.83; 95% CI, 0.70–0.99). The absolute difference in intracranial bleeding rates also 
favoured edoxaban in this analysis (68). 
 
Therefore, subgroup analyses of phase III trials highlight some differences in the relative 
safety of NOACs compared to warfarin. To explore this issue further, data from the RE-LY, 
ARISTOTLE and ROCKET-AF trials were extracted with reference to the rates of major 
bleeding in patients aged <75 years or ≥75 years old (raw data from the ENGAGE AF-TIMI 
48 trial were not available). The findings of the analysis (Figure 1) suggest that, overall 
NOACs are favourable to warfarin in preventing major bleeding, in patients <75 years old. 
However, this effect appears to be less pronounced in patients ≥75 years old, particularly for 
dabigatran and rivaroxaban, while apixaban appears to have a favourable bleeding risk 
compared to warfarin therapy. The general trend for the three NOACs in this analysis 
suggests consistent favourability over warfarin even in older patients, although this effect is 
largely attributable to the favourable effects of apixaban.  
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Further randomised trial data would provide insights into the true effect of age on NOAC 
safety, when taking into account age-associated risk factors, such as hypertension, renal 
impairment and polypharmacy. Untangling comorbidities in the elderly is challenging 
however, as declining renal function in elderly patients may confound the observed benefit 
seen with age alone, while the frailty phenotype will likely become a more important 
subgroup in the next ten years. 
 
The selection of NOACs based on patient age is a complex process and care must be taken 
to ensure that the comorbidities associated with increased age are considered during this 
decision-making process. Hypertension, congestive heart failure, type 2 diabetes and 
previous stroke are all risk factors for future stroke and bleeding risk and are more common 
in the elderly population than in younger patients (69). Similarly, renal function declines with 
age (70) and polypharmacy increases with age (71); both may influence the effectiveness 
and safety of NOAC therapy (72). Therefore, basing the selection of NOACs on age alone 
may be inappropriate, unless these other factors are also considered. Dose-reduced 
regimens of NOACs may also be justified based on patient age, in combination with other 
factors (i.e. body weight, concomitant medication, and renal function) (73).  
 
Current European recommendations (73) advise dose reductions of NOACs in patients aged 
over 75 years only where other risk factors are present, such as low body weight or renal 
impairment, with the exception of dabigatran where dose reduction from 150mg to 110mg is 
advised in patients aged >80 years, due to the increased risk of bleeding in older patients on 
the higher dose. 
 
Gender 
Compared with men, women develop AF at an older age (74–76) and have a higher risk of 
stroke (77). Being female affords an increased risk of stroke, which is reflected in  the 
CHA2DS2-VASc score and female gender is also a risk factor for maintaining time in the 
therapeutic range of warfarin therapy, reflected in the SAMe-TT2R2 score (10). Even when 
women spend a significant amount of time within the therapeutic range (>66%) their risk of 
stroke is higher than for men (78). Whilst women have an increased stroke risk compared to 
men, there is no significant difference in composite cardiovascular death and stroke/SEE 
(79). The reasons underlying the increased risk of stroke in women with AF are unclear, 
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although an increased rate of hypertension (80) and structural differences in the left atrium 
compared with men (81), have been proposed to account for some of this increased risk. 
Regardless of the underlying reasons, the efficacy and safety of NOACs in women with AF 
remains uncertain at present. 
 
A meta-analysis of NOACs versus warfarin showed that women with AF have a greater risk 
of cerebrovascular events and systemic embolism compared with men, but that these 
differences are not seen when both sexes are treated with NOACs (apixaban, dabigatran or 
rivaroxaban) (82). This meta-analysis also found that women had a lower risk of major 
bleeding then men on NOAC therapy (OR 0.849, CI 0.745-0.955, p=0.007). An indirect 
comparison of NOAC therapy in women suggested that there were no differences in the 
safety and efficacy of NOACs in this population (83).  
 
Our analysis of data extracted from phase III NOAC trials in patients with AF was used to 
explore the effect of gender on a single key safety outcome: major bleeding (Figure 2). Data 
were only available for absolute patient numbers from the RE-LY, ARISTOTLE and 
ROCKET-AF trials, while data on all-cause mortality were not available for all studies 
according to patient gender. The results of this analysis suggest that there is little difference 
in the rates of major bleeding with individual NOACs when comparing male and female 
patients. In both male and female patients the NOACs collectively showed statistically 
favourable results compared to warfarin therapy. Apixaban may be associated with a more 
pronounced reduction in major bleeding versus warfarin therapy in women compared with 
men.  
 
Therefore, the available evidence suggests that safety outcomes for men and women are 
similar, with a reduction in major bleeding compared warfarin therapy, regardless of the 
individual NOAC used. Therefore, no specific agent may be preferred based on patient 
gender alone. Data on edoxaban suggests that outcomes in men and women are very 
similar (84), but pending a more robust analysis of data on edoxaban, and head-to-head 
trials comparing the safety of NOACs, NOAC selection in both men and women should be 
based on patient preference and clinical characteristics (e.g. renal function, bleeding risk 
factors).  
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Accumulated risk factors for stroke 
 
As noted above, there are multiple risk factors for stroke that are of particular relevance in 
patients with AF. The CHA2DS2-VASc stroke risk stratification score identifies congestive 
heart failure, hypertension, previous stroke/TIA/thromboembolic event, vascular disease, 
type 2 diabetes, female gender and advanced age (≥75 years) as risk factors for stroke in 
patients with AF (85). This score is beneficial in refining the identification of low- and 
intermediate-risk patients in a patient population with CHADS2  0–1 (86). 
 
Most guidelines currently recommend the use of the CHA2DS2-VASc score to determine the 
indication for antithrombotic therapy in patients with AF (87–89). Current European 
guidelines suggest that a threshold CHA2DS2-VASc score of ≥2 for men and ≥3 for women 
should be used to (strongly) recommend oral anticoagulant therapy whilst for 1 stroke risk 
factor (ie CHA2DS2-VASc score of 1 for men and 2 for women, OAC ‘should be considered’ 
(89).  The latter reflects the lack of RCTs specifically studying patients with 1 stroke risk 
factor. However, stroke rates vary depending on the risk factor that is present (64). One 
analysis from a National Primary Care Database found that the stroke rate was highest 
when advanced age or previous stroke was present, compared to other risk factors (92). 
Therefore, it remains challenging to accurately stratify patients according to stroke risk 
based on the use of standardised risk scoring; the impact of individual risk factors appears to 
be important in AF patients on the borderline of the treatment threshold (93).   
 
The 2018 ACCP guidelines recommend a stepwise approach, to initially identify low risk 
patients (CHA2DS2VASc 0 in males or 1 in females), for whom no antithrombotic therapy is 
recommended; the next step is to offer stroke prevention (i.e. oral anticoagulants) to those 
with ≥1 stroke risk factors (25). This reflects that the default strategy should be to offer 
stroke prevention unless the patient is low risk. 
 
The phase III NOAC trials utilised CHADS2 scores to calculate patient risk of stroke and to 
stratify patient subgroups, hence the CHADS2 score is used in analyses of data from these 
trials. It should be noted that the ENGAGE AF-TIMI 48 trial used a CHADS2 score ≥2 as an 
inclusion criterion for patients in both the edoxaban and warfarin treatment groups. As a 
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result, it is not possible to compare the safety of edoxaban in patients with CHADS2 <2 with 
those achieving higher scores, based on phase III trial data.  
 
Data extracted from phase III trials indicated that all NOACs were associated with a 
reduction in major bleeding compared to warfarin, regardless of the CHADS2 score (Figure 
3). This effect was statistically significant only in patients with CHADS2 scores of 2 or more 
(P <0.001), indicating that NOACs may be more favourable than warfarin in preventing major 
bleeding in patients at a greater risk of stroke. This effect was less pronounced for all-cause 
mortality (Figure 4), although the NOACs remained favourable compared with warfarin 
therapy, although this was not statistically significant. Further data on apixaban suggested 
that patients with CHADS2 >3 showed the greatest reduction in stroke, with better efficacy 
and safety than in patients with lower CHADS2 scores (94). In the RE-LY study, the greatest 
absolute risk reduction in stroke is seen in patients with the highest risk of stroke or bleeding 
treated with dabigatran versus warfarin (95). 
 
Analyses of the NCB of NOACs have suggested that these agents are generally favourable 
compared to warfarin for both efficacy and safety outcomes (96). When the risk of bleeding 
and stroke are both elevated, the NOACs generally demonstrate a greater NCB compared 
with warfarin, suggesting the broad application of NOACs in patients with a number of 
bleeding risk factors and stroke risk factors (96). However, these analyses are based on 
indirect data comparisons excluding edoxaban and head-to-head trials would be needed to 
clarify the relative safety of individual NOACs. An analysis of the NCB of edoxaban 
suggested that the efficacy and safety of the high-dose regimen (60/30mg) was favourable 
compared to warfarin, even in patients at higher risk of bleeding or stroke (38).  
 
In summary, there are insufficient data to suggest that one NOAC may be preferable over 
another based on stroke risk stratification using the CHADS2 or CHA2DS2-VASc, where ≥2 
risk factors are present.  
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Primary versus secondary stroke prevention 
 
The phase III NOAC trials generally found that patients with previous stroke/transient 
ischaemic attack (TIA) had a higher rate of stroke than patients without a history of 
stroke/TIA. Enrolment rates of patients with previous stroke/TIA did vary between phase III 
trials however, with ROCKET-AF showing the highest rate of patients with previous 
stroke/TIA (55%) (31). Subgroup analyses of trials exploring the use of dabigatran, 
rivaroxaban and apixaban found similar efficacy and safety with these NOACs, regardless of 
stroke/TIA history (97–99). A meta-analysis of dabigatran, rivaroxaban and apixaban found 
that NOACs were comparable to warfarin for the prevention of stroke/SEE in patients with a 
history of stroke/TIA, with indirect comparisons of NOACs demonstrating no significant 
difference in stroke, disabling stroke, or all-cause mortality (100). However, the rate of 
intracranial bleeding was lower with NOACs compared with warfarin in patients with previous 
stroke/TIA (71).  
 
For edoxaban, pre-specified analyses have shown a consistent level of efficacy and safety 
compared with warfarin in patients with or without a previous history of stroke/TIA (30). A 
recent formal subgroup analysis found that the high-dose edoxaban regimen (60mg reduced 
to 30mg, based on patient characteristics) had comparable efficacy for stroke prevention 
and improved safety compared with warfarin in patients with or without a history of 
stroke/TIA (101).  
 
Phase III trial data was analysed in order to explore the relative safety of NOACs based on 
the use of NOACs for primary versus secondary stroke prevention in the AF population 
(Figures 5 and 6). The findings showed that the NOACs were favourable compared to 
warfarin in both primary and secondary stroke prevention contexts, when the outcome of 
major bleeding was considered (P<0.001 for both primary and secondary populations; 
Figure 5). The strongest benefits were apparent with apixaban and edoxaban, while the rate 
of major bleeding with rivaroxaban, in particular, was less favourable compared with warfarin 
in the primary prevention context. When all-cause mortality was considered as a key safety 
outcome, the NOACs performed similarly and were favourable compared to warfarin for both 
primary and secondary stroke prevention populations, although these effects did not reach 
statistical significance (Figure 6).  
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In summary, the NOACs appear to be associated with a lower rate of major bleeding than 
warfarin in patients receiving anticoagulation for primary or secondary stroke prevention, 
with the exception of rivaroxaban. Edoxaban and apixaban had particularly favourable safety 
outcomes in both patient populations.  
 
Additional safety considerations 
 
The heterogeneity of patients with AF adds to the complexity of managing patients 
effectively, particularly when balancing bleeding risk and anticoagulant effect. Patients with 
impaired renal and liver function are at risk of increased exposure to NOACs and dose 
adjustment is advised according to available guidelines (102) in order to maintain 
comparable efficacy and safety to warfarin use. In patients with chronic liver disease data 
are limited for NOACs versus warfarin, but a recent retrospective cohort study suggests 
similar bleeding rates for both anticoagulant approaches (103). More data are needed to 
clarify the relative risks and benefits of NOACs compared to warfarin in liver disease.  
 
Asian patients with AF have different characteristics than non-Asian patients with AF, 
including an increased tendency towards bleeding and a reduced chance of achieving 
therapeutic INR levels with warfarin therapy (104,105). Warfarin use in Asian patients with 
AF is associated with higher rates of stroke than that seen in non-Asians (104). The use of 
NOACs in the Asian population has been shown to reduce the risk of stroke and does not 
lead to increased bleeding events compared with warfarin therapy, based on Phase III trial 
data (106). Similarly, real-world data suggest that the risk of ischaemic stroke is similar with 
NOACs and warfarin use in Asian patients, while the risk of ICH is lower with NOACs (107). 
 
One of the perceived advantages of warfarin therapy is the ability to monitor the 
anticoagulation effect through INR levels, which provides reassurance to clinicians that 
effective anticoagulation is achieved and maintained. Uncertainty over the ‘true’ 
anticoagulant effects of NOACs, based on specific plasma markers, may lead to doubt over 
the achievement of effective anticoagulation among clinicians (108). However, as NOACs 
achieve a more predictable anticoagulant effect than warfarin, plasma level monitoring of 
NOACs is not recommended on a routine basis. Indeed, plasma levels may not be indicative 
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of anticoagulant effect and limited data support this strategy (102). Therefore, there is no 
clear place for monitoring plasma levels of NOACs to maximise benefits or minimise risks in 
routine practice at present.  
 
Despite the many advantages of NOACs compared to VKA therapy, careful decision-making 
is required to ensure the safety of selecting on option over another. As more data emerge 
from clinical trials and real-world analyses, the use of NOACs is becoming more diverse, 
replacing VKA therapy in many contexts as a safe, reliable and effective treatment approach 
(109). VKA therapy still has a role to play in many contexts, including situations where 
NOACs are contraindicated (e.g. renal failure). However, uncertainty over the relative 
efficacy of different NOACs and clinical inertia often accounts for the preference for VKA 
therapy in clinical practice (110) and this must be addressed through careful examination of 
NOAC safety and clarity in clinical guidelines to ensure patient safety and the effectiveness 
of anticoagulation.  
 
Limitations 
 
All of the analyses presented in this manuscript are based on indirect comparisons of NOAC 
patient subgroups, which have inherent limitations compared to analyses based on head-to-
head trials (111). However, no head-to-head trials exist for the NOACs and therefore indirect 
comparisons of data may provide an insight into the comparative effects of the drugs, 
provided key limitations are borne in mind (35,112). For instance, the design of the phase III 
NOAC trials varied, with different criteria for patient selection, variable levels of 
anticoagulation control with warfarin, and different approaches to drug comparison (e.g. the 
RE-LY trial was a three-arm open clinical trial comparing two doses of dabigatran and 
warfarin, while the remaining trials were double-blind and dose adjustments were made 
depending on patient characteristics).  
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  Conclusion 
 
This review highlights the importance of considering patient subgroups and specific stroke 
risk factors when initiating antithrombotic therapy in patients with AF. The safety of the 
NOACs compared to warfarin was generally favourable across different patient subgroups. 
However, certain NOACs may be preferable to warfarin in some subgroups, based on 
indirect analyses. It will be important to confirm these findings in head-to-head trials in order 
to effect changes in clinical practice consistent with optimisation of patient safety.   
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Table 1. Summary of data from phase III clinical trials of non-vitamin K antagonists (NOACs) for the prevention of stroke and 
systemic embolic events in patients with atrial fibrillation. TTR, time in therapeutic range.  
 
Trial N Drug and dose Mean TTR in 
warfarin arm 
of study (%) 
Relative risk (95% confidence interval) vs. warfarin 
Stroke  or 
systemic 
embolism 
Major 
haemorrhage 
Intracranial 
haemorrhage 
All-cause 
mortality 
RE-LY (29) 18,113 Dabigatran 150 
mg twice daily 
 
Dabigatran 110 
mg twice daily 
64 0.66  
(0.53–0.82) 
 
0.91  
(0.74–1.11) 
 
0.93  
(0.81–1.07) 
 
0.80  
(0.69–0.93) 
0.40  
(0.27–0.60) 
 
0.31  
(0.20–0.47) 
0.88  
(0.77–1.00) 
 
0.91  
(0.80–1.03) 
ROCKET-AF 
(31) 
14,264 Rivaroxaban 20 
mg once daily 
55 0.88 
(0.75–1.03) 
1.04  
(0.90–1.20) 
0.67 
(0.47–0.93) 
0.85 
(0.70–1.02) 
ARISTOTLE 
(13) 
18,201 Apixaban 5 mg 
twice daily 
62 0.79 
(0.66–0.95) 
0.69  
(0.60–0.80) 
0.42 
(0.30–0.58) 
0.89 
(0.80–0.99) 
ENGAGE AF-
TIMI 48 (30) 
21,105 Edoxaban 60 mg 
once daily  
 
Edoxaban 30 mg 
once daily 
68 0.87 
(0.73–1.04) 
 
1.13 
(0.96–1.34) 
0.80 
(0.71–0.91) 
 
0.47 
(0.41–0.55) 
0.47 
(0.34–0.63) 
 
0.30 
(0.21–0.43) 
0.92 
(0.83–1.01) 
 
0.87 
(0.79–0.96) 
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Table 2. Summary of phase III clinical trial data for the NOACs compared to warfarin in patients aged 75 years or older. 
NB: Relative risk data according to age subgroups are not available for edoxaban- hazard ratios are presented.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Trial 
N (aged 
75 years 
or over) 
Drug and dose Relative risk (95% confidence interval) vs. warfarin* 
Stroke or 
systemic 
embolism 
Major 
bleeding 
Intracranial 
bleeding 
Gastrointestinal 
bleeding 
RE-LY  7,258 Dabigatran 150 
mg twice daily 
 
Dabigatran 110 
mg twice daily 
0.67 
(0.49–0.90) 
 
0.88 
(0.66–1.17) 
 
1.18  
(0.98–1.42) 
 
1.01 
(0.83–1.23) 
0.42 
(0.25–0.70) 
 
0.37  
(0.21–0.64) 
1.79  
(1.35–2.37) 
 
1.39  
(1.03–1.98) 
ROCKET-AF  6,229 Rivaroxaban 20 
mg once daily 
0.80 
(0.63–1.02) 
1.11 
(0.92–1.34) 
0.80 
(0.50–1.28) 
N/A 
ARISTOTLE  5,678 Apixaban 5 mg 
twice daily 
0.71 
(0.53–0.95) 
0.64  
(0.52–0.79) 
0.34 
(0.20–0.57) 
N/A 
ENGAGE AF-
TIMI 48  
8,474 Edoxaban 60 mg 
once daily 
Edoxaban 30 mg 
once daily 
0.83 
(0.66–1.04) 
1.12 (0.91–
1.37) 
0.83 
(0.70–0.99) 
0.47 (0.38–
0.58) 
0.40 
(0.26–0.62) 
0.30 (0.19–
0.49) 
1.32 
(1.01–1.72) 
0.72 (0.63–0.98) 
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Figure 1. Major bleeding among individuals receiving anticoagulation aged <75 and 
≥75 years. 
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Figure 2. Major bleeding among female and male individuals receiving 
anticoagulation. 
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Figure 3. Major bleeding among individuals receiving anticoagulation for CHADS 0-1 
vs CHADS 2-6.  
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Figure 4. All-cause mortality among individuals receiving anticoagulation for CHADS 
0-1 vs CHADS 2-6.  
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Figure 5. Major bleeding among individuals receiving anticoagulation for primary 
versus secondary prevention. 
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Figure 6. All-cause mortality among individuals receiving anticoagulation for primary 
versus secondary prevention. 
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